India, April 27 -- Sun Pharmaceutical Industries Ltd has announced the acquisition of US-based Organon & Co in an all-cash transaction, valuing the deal at an enterprise value of USD 11.75 billion—one of the largest overseas acquisitions by an Indian company.
Under a definitive agreement, Sun Pharma will acquire all outstanding shares of Organon at USD 14 per share in a fully cash-based deal, the company said in a statement on Monday.
Organon, a global healthcare firm, was spun off from Merck & Co. (known as MSD outside the US and Canada) in 2021. The company operates six manufacturing facilities across the European Union and other emerging markets.
Published by HT Digital Content Services with permission from Dion Global Solutions...